Europe
There was a fair amount of clinical trial news last week. Here’s a look.
In his fifth year as CEO, his take-home was about $20.15 million – an almost $1.7 million base pay plus $13.5 million in stock awards, with another $5 million in incentive plan pay with “other” pay.
In 2019, Novartis subsidiary AveXis announced it acquired a manufacturing facility in Colorado to provide additional production capacity for Zolgensma. Just two years later, the facility will be closed and 400 people will be without a job.
What has been learned about SARS-CoV-2, the virus that causes COVID-19, in only about 15 months, is truly a historical scientific achievement. And new information continues to come in.
Several new initial public offering (IPO) announcements have been made by international and U.S.-based biopharmaceutical and biotechnology companies in the past couple of days.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
In a stunning fall from grace playing out this week, former Operation Warp Speed vaccine czar, Dr. Moncef Slaoui, issued a statement Thursday morning, as news emerged that he has resigned from additional biotech posts.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
AstraZeneca released primary analysis that the vaccine demonstrated 76% efficacy against symptomatic COVID-19, 100% efficacy against severe or critical disease and hospitalizations and 85% efficacy against symptomatic COVID-19 in people 65 years and older.
PRESS RELEASES